Lymphoma Australia nwere ihe ịga nke ọma n'inweta onyinye zuru ụwa ọnụ sitere na AbbVie iji mee ajụjụ ọnụ na ndị ọkachamara Australia na mba ụwa na lymphoma na ọrịa leukemia lymphocytic na-adịghị ala ala (CLL). Ajụjụ ọnụ ndị a ga-akọ akụkọ kachasị ọhụrụ gbasara ule nyocha nke lymphoma / CLL na ọmụmụ ihe sitere na gburugburu ụwa ma gosipụta ya n'oge nzukọ ASH. A ga-ekekọrịta ajụjụ ọnụ ndị a gburugburu ụwa site na otu ndị na-akwado ndị ọrịa.
Lymphoma Australia mere ihe fọrọ nke nta ka ọ bụrụ ajụjụ ọnụ 40 n'ime ụbọchị 4 nke nzukọ ahụ, anyị ga-achọ ịnye gị ekele sitere n'obi sitere na obodo lymphoma / CLL nye onye ọ bụla na-ekerịta oge, ihe ọmụma na nkà ha.
B-cell lymphoma
Dr Laurie Sehn – ASH Lymphoma Mmelite.
Dr Laurie Sehn sitere na British Columbia Cancer Center si Vancouver, Canada bụ onye isi oche ndị ndụmọdụ ahụike maka International Lymphoma Coalition. Dr Sehn tụlere ụfọdụ isi ihe dị na usoro ọgwụgwọ ọhụrụ ndị e gosipụtara n'oge nzukọ ASH maka lymphoma. Ndị a gụnyere Polatuzumab (ọgwụ mgbochi antibody conjugate) maka mgbasa nnukwu B-cell lymphoma (DLBCL) na Mosunetzumab - (bispecific antibody) eji maka B-cell na-abụghị Hodgkin lymphomas.Dr Chan Cheah - Ọmụmụ ihe ọmụmụ TG-1701 nlọghachite ma ọ bụ nke na-emegharị B-cell Lymphoma.
A/Prof Chan Cheah, onye ndụmọdụ gbasara ahụike ahụike, ụlọ ọgwụ Sir Charles Gairdner, Hollywood Private Hospital & Blood Cancer Research WA, na Perth, Western Australia, tụlere ihe ngosi akwụkwọ mmado na ASH nke nnwale emere na Australia site na iji ọgbọ ọhụrụ Bruton's Tyrosine Kinase. (BTK) inhibitor a na-akpọ TG-1701 na-eji na ndị ọrịa nwere nlọghachi azụ / refractor B-cell malignancies. A na-enye ọgwụ ọnụ a dị ka otu onye na-ejikọta ya na umbralisib (PI3K inhibitor) na ubiltuximab (glycoengineered anti-CD20 monoclonal antibody).Dr George na-eso – Mmelite Lymphoma.
Dr George Follows bụ Lymphoma/CLL Clinical Lead maka Cambridge na ọ na-ejidekwa ọtụtụ nhọpụta gụnyere onye isi oche UK CLL forum. Dr Follows tụlere mmelite maka lymphoma nke ewepụtara n'oge nzukọ mmasị ASH. Ndị a gụnyere usoro nke mbụ nke na-eji ọgwụ ọhụrụ a na-akpọ Monunetuzumab nke bụ ihe mgbochi monoclonal bispecific nke na-elekwasị anya CD3 na CD20 ma mee ka nzaghachi na-adịgide adịgide na ndị ọrịa nwere lymphoma B-cell na-abụghị Hodgkin na-emegharịghachi ma ọ bụ refractory, gụnyere ndị ọrịa lọghachiri na CAR T. - ọgwụgwọ cell.
Dr Stephen Schuste - Mosunetzumab na-ebute mgbaghara zuru oke na ndị ọrịa nwere lymphoma B-cell na-abụghị Hodgkin.
The bispecific monoclonal antibody Mosunetuzumab, nke lekwasịrị CD3 na CD20, dugara nzaghachi na-adịgide adịgide na ndị ọrịa nwere B-cell non-Hodgkin lymphoma (NHL), ọbụlagodi ndị nwere ọrịa na-alaghachi azụ ma ọ bụ na-anabata chimeric antigen receptor (CAR) T- ọgwụgwọ cell. Dr Schuste na-atụle usoro ọmụmụ I / Ib na-aga n'ihu (GO29781; NCT02500407) nke mosunetuzumab na ndị ọrịa nwere B-cell non-Hodgkin lymphoma (NHL), ndị na-alaghachi azụ / refractory (R / R) na ọgwụgwọ CAR-T ma ọ bụ maka onye a. igbu oge na ọgwụgwọ dị irè na-ewepu usoro a. Nkwado data izizi na mosunetzumab nwere nnabata dị mma yana ịdịgide adịgide na R/R B-cell NHL agwọgoro nke ọma.
Dr John Leonard - isi ihe sitere na nzukọ maka lymphoma.
Dr Leonard kwurịtara echiche ndị ọkachamara ya site na ihe ngosi lymphoma n'oge nzukọ ahụ. Ọ tụlere ọtụtụ isiokwu gụnyere: • Follicular lymphoma - chemo free regimens • Diffuse Large B-cell Lymphoma - ahụike ọkpụkpụ na ndị ọrịa post R-CHOP na CAR T-cell therapy • Mantle Cell Lymphoma - ọgwụ ọhụrụ jikọtara ya na chemotherapy • Nnwale ọbara DNA • Ọgwụ mgbochi ọrịa Lymphoma
Ọrịa leukemia Lymphocytic na-adịghị ala ala (CLL) na obere ọrịa leukemia lymphocytic (SLL)
Dr Brian Koffman - mmelite CLL & nkwado ndị ọrịa.
Dr. Koffman, bụ dọkịta a ma ama, onye nkụzi na prọfesọ ụlọ ọgwụ tụgharịrị onye ọrịa CLL, ararala onwe ya nye nkuzi na inyere ndị obodo CLL aka kemgbe nchọpụta ya na 2005. Dr. Koffman kwenyere na ọnọdụ abụọ ya dị ka dọkịta na onye ọrịa na-enye ihe pụrụ iche. ahụmahụ na nghọta nke na-enye ya ohere ịnye nkọwa doro anya banyere nsogbu ndị dị mgbagwoju anya na ịkwado ndị ọrịa ibe ya ma gwa ndị nlekọta ahụike ibe ya. Nke a dị mkpa karịsịa n'ihi ọnọdụ ọgwụgwọ na-agbanwe ngwa ngwa. Dr Koffman bụ onye nchoputa nke CLL Society, USA. Dr Koffman tụlere mmelite CLL sitere na ogbako ahụ gụnyere mmelite gbasara ọgwụgwọ CAR T-cell, ibrutinib, acalabrutinib, usoro ọgwụ na usoro ọgwụgwọ dị iche iche. Ọ tụlekwara njikwa kacha mma nke CLL, gụnyere nyocha mkpụrụ ndụ ihe nketa tupu ọgwụgwọ yana ndị ọrịa nwere ọrịa na-enweghị mgbanwe, 17p del ekwesịghị inwe chemotherapy, kama ọgwụgwọ ezubere iche.
Prọfesọ John Gribben na Deborah Sims - Nyochaa ọgwụgwọ CLL.
Prọfesọ Gribben tụlere echiche ya banyere mmelite sitere na nzukọ ahụ ebe ọtụtụ n'ime ihe ngosi ahụ kwadoro na ọgwụgwọ ndị a na-eji dị mma ebe ọ bụ na enweela ogologo oge. Site n'ịgbaso ogologo oge na-abịakwa mara ihe ọhụrụ toxicities nwere ike ịpụta. Anyị nwere ike ịkụziri ndị ọrịa nke ọma site n'inwe echiche ka mma nke ihe ha ga-atụ anya ya. Ọ tụlekwara usoro ọgwụgwọ ọhụụ ọhụrụ nke ewepụtara, ọ bụghị naanị na CLL, mana lymphomas ndị ọzọ dị ka Follicular lymphoma & Mantle cell lymphoma. Enwekwara ọtụtụ nnwale ụlọ ọgwụ nke mbụ nwere ọgwụ ọhụrụ na-egosi nkwa. Nchegbu na-esote bụ na usoro ọgwụgwọ ọhụrụ ndị a na usoro ọgwụgwọ ngwakọta, na-abịa na-abawanye ego maka usoro ahụike.
Prọfesọ Stephan Stilgenbauer na Deborah Sims - Mmelite na njikwa nke CLL/SLL.
Prọfesọ Stilgenbauer nyere nkọwa nke mmelite ọgwụgwọ maka ndị ọrịa nwere CLL / SLL site na nzukọ ASH. Ọ na-atụle iji usoro ọgwụgwọ ọhụrụ dị ka ndị na-alụbeghị di ma ọ bụ nwunye na nchikota nke na-enwe mmetụta dị ịrịba ama maka ndị ọrịa, karịsịa ndị nwere ọrịa na-adịghị agbanwe agbanwe na ya mere anaghị anabata nlekọta nke chemotherapy omenala. Usoro ọgwụgwọ n'ọdịnihu maka CLL/SLL nwere ike ịbụ na chemotherapy nwere ike ịghọ ọgwụgwọ nke abụọ ma ọ bụ nke atọ.
A/Prof Constantine Tam na Deborah Sims – CLL & Mantle Cell Lymphoma.
A/Prof Constantine Tam, Peter MacCallum Cancer Center, RMH & St Vincent's Hospital gwara Deborah Sims, si Lymphoma Australia okwu. Dr Tam na-enye nghọta ya site na isi ihe sitere na nzukọ ahụ na CLL na Mantle cell lymphoma. O nyere nkọwa nke ihe ngosi 3 ya nke ọma maka ọrịa leukemia Lymphocytic Chronic Lymphocytic (CLL) & Small Lymphocytic Lymphoma (SLL).
Dr George na-eso – mmelite CLL.
Dr George Follows si UK na Lymphoma Australia kwurịtara okwu na nzukọ American Society of Hematology (ASH) e mere na nso nso a na Orlando, USA. Dr Follows bụ Lymphoma/CLL Clinical Lead maka Cambridge na ọ na-ejidekwa ọtụtụ nhọpụta gụnyere onye isi oche UK CLL forum. Ọ tụlere mmelite ọhụrụ na nsonaazụ nyocha nke ewepụtara na nzukọ ASH na CLL.
Dr Nitin Jain na Deborah Sims - Ibrutinib & Venetoclax na ndị ọrịa nwere CLL.
Dr Nitan Jain bụ osote prọfesọ na Ngalaba Leukemia na Mahadum Texas MD Anderson Cancer Center na Houston, Texas, USA. Dr Nitan kwurịtara ihe ngosi 2 ya n'oge nzukọ ASH nke ọmụmụ 2 a na-eme na MD Anderson Cancer Center site na iji Ibrutinib na venetoclax jikọtara ya na ndị ọrịa nwere ọrịa leukemia lymphocytic na-adịghị ala ala (CLL) na ọgwụgwọ mbụ na ndị nwere ọrịa nlọghachi azụ / refractory. Nsonaazụ gosiri na n'ime otu abụọ ọgwụgwọ jikọtara ya na iji ibrutinib na venetoclax bụ usoro ọgwụgwọ ọnụ na-enweghị chemotherapy dị irè maka ndị ọrịa nwere CLL na ọmụmụ ihe ga-aga n'ihu.
Dr Tanya Siddiqi - CAR T-cell na CLL na-alaghachi azụ / refractory.
Dr Tanya Siddiqi bụ Director, Chronic Lymphocytic Leukemia Programme, Toni Stephenson Lymphoma Center na A/Prof Department of Hematology & Hematopoietic Transplantation na City of Hope National Medical Center, Duarte, USA. Dr Siddiqi kwurịtara ihe ngosi ya n'oge nzukọ nke oge m na-amụ na-agwọ ndị ọrịa na-emegharịghachi azụ ma ọ bụ ndị na-atụgharị uche na CLL. Ndị ọrịa niile enwetabula opekata mpe ọgwụgwọ ọkọlọtọ 3, gụnyere ibrutinib na ọkara ndị ọrịa anatakwala venetoclax. Ọmụmụ ihe ahụ gwọọ ndị ọrịa 23 nwere ọgwụgwọ CAR T-cell ebe ihe karịrị 80% nwetara nzaghachi na-adịgide adịgide n'ime ọnwa 6. Usoro na-aga n'ihu.
Prọfesọ John Seymour - Nchịkọta nke ọmụmụ Murano - CLL/SLL.
Prọfesọ Seymour gosipụtara nyocha nke afọ anọ nke ọmụmụ Murano nke na-akwado uru na-adịgide adịgide nke Venetoclax na rituximab nwere oke na nlọghachi azụ ma ọ bụ na-egbochi ọrịa leukemia lymphocytic na-adịghị ala ala (CLL). Venetoclax (Ven) bụ onye na-emechi ọnụ ọnụ nke ukwuu nke na-egbochi onye na-achịkwa apoptosis BCL-2, nke egosipụtara na CLL. MURANO (ihe ọmụmụ Phase III nke enweghị usoro) atụnyere VenR ogologo oge yana ọkọlọtọ bendamustine-rituximab (BR) na R/R CLL. Ọganihu na-enweghị ọganihu dị elu (PFS) nke VenR megide BR ka e guzobere na nyocha nke mbụ akwadoro (Seymour et al. N Engl J Med 2018); A na-ahụta uru PFS na-aga n'ihu na nsonye ogologo oge yana mgbe ndị ọrịa niile mechara ọgwụgwọ.
Prọfesọ Peter Hillmen - Ihe ịma aka na mpaghara ọgwụgwọ CLL/SLL.
Prọfesọ Hillman na-atụle ụfọdụ n'ime ihe ịma aka nke ọnọdụ ọgwụgwọ na-agbanwe ngwa ngwa maka CLL/SLL nwere ọtụtụ ọgwụgwọ ọhụụ na ahịa.
Prọfesọ Peter Hillmen - mmelite CLL sitere na ASH 2019.
Prọfesọ Hillmen tụlere ụfọdụ n'ime isi ihe dị mkpa sitere na nzukọ ahụ na nnwale ọgwụgwọ ọhụụ ejiri na ntọala ihu ụzọ ewepụtara gosipụtara nsonaazụ dị mma site na iji ibrutinib (BTK inhibitor), acalabrutinib (ọgbọ ọhụrụ BTK inhibitor), venetoclax (BCL2 inhibitor). ) na iji usoro ọgwụgwọ ngwakọta. Ọ tụlekwara ule ụlọ ọgwụ na ọnọdụ nlọghachi azụ na-egosi nsonaazụ dị mma nke gụnyere ọgwụgwọ CAR T-cell. Daalụ Leukemia Care maka ịkọrọ ajụjụ ọnụ a na Lymphoma Australia.
Prọfesọ Miles Prince - Nnwale mkpụrụ ndụ ihe nketa (CLL/SLL) na ọgwụgwọ T-cell CAR.
Prọfesọ Prince kwurịtara echiche ya banyere isi isiokwu ndị nwere mmasị maka lymphoma site na nzukọ ahụ. Ọ tụlere na ụzọ kachasị mma isi gwọọ lymphoma onye ọrịa, ọ dị mkpa ka a ghọta ihe ọ chọpụtara na mara ya nke ọma. E gosiputara na ndị ọrịa a chọpụtara na ha nwere CLL/SLL kwesịrị ịnwale mkpụrụ ndụ ihe nketa tupu ha enweta ọgwụgwọ. Ndị ọrịa enweghị mgbanwe na TP53 mutated CLL/SLL, chemotherapy egosila na ọ naghị adị irè maka otu onye ọrịa a. Na USA na UK (na ụfọdụ mba Europe) a na-akwado ndị ọrịa ka ha nweta Ibrutinib n'ihu-line, Otú ọ dị, nke a ka na-adịghị na Australia, ebe ndị ọrịa na-enweta chemo-immunotherapy na ibrutinib na ọgwụgwọ nke abụọ.
Na-agbasa nnukwu mkpụrụ ndụ B-cell Lymphoma (DLBCL)
A/Prof Chan Cheah – Lymphoma ike ike, na-agbasa nnukwu mkpụrụ ndụ B cell lymphomas.
A/Prof Cheah na-emegharị akwụkwọ akụkọ ahụ "Aggressive Lymphoma (Diffuse Large B-cell na ndị ọzọ na-eme ihe ike b-cell na-abụghị Hodgkin lymphomas) - nsonaazụ sitere na ule ụlọ ọgwụ ndị a na-atụ anya: na-eme ka chemotherapy na-aga n'ihu" nnọkọ na Sunday 8th December na ASH 2019.
Dr.
Dr Westin tụlere ụfọdụ isi ihe sitere na ogbako na DLBCL gụnyere ọgwụgwọ CAR T-cell na mmelite sitere na ọmụmụ ndị na-eji obere chemotherapy na ya mere na-emeziwanye mmetụta ndị na-egbu egbu maka ndị ọrịa.
Ọkpụkpụ Lymphoma
Dr Loretta Nastoupil - Ọmụmụ lymphoma follicular - Akụkụ 1.
Dr Nastoupil na-ekwurịta nsonaazụ nke usoro ọmụmụ ya nke Abụọ nke Obintuzumab (ụdị II anti-CD20 monoclonal antibody) na Lenalidamide (onye na-ahụ maka immunomodulatory) na nke a na-agwọbeghị mbụ, nnukwu tumor FL. A hụrụ nchikota usoro ọgwụgwọ a ka ọ na-anabata nke ọma ma dị irè na nyocha gara aga maka ndị ọrịa a na-emeso na nlọghachi azụ ma ọ bụ refractory FL.
Dr Loretta Nastoupil - Ọmụmụ lymphoma follicular - Akụkụ 2.
Dr Nastoupil kwurịtara nsonaazụ nke ọmụmụ ihe nke abụọ nke Obintuzumab (ụdị II anti-CD20 monoclonal antibody) na Lenalidamide (onye na-ahụ maka immunomodulatory) na nke a na-agwọbeghị mbụ, nnukwu tumor FL. Ọmụmụ ihe ọzọ maka nke a dị irè, usoro ọgwụgwọ mgbochi ọrịa na FL adịghị agwọ ya kwesịrị ekwesị. Dr Nastoupil na-atụle ihe kpatara usoro a dị irè na nke ọma maka ndị ọrịa ọ bụla nwere lymphoma Follicular.
A/Prof Chan Cheah – Nwelite nnwale ụlọ ọgwụ Follicular lymphoma.
Dr Cheah tụlere ihe ngosi nke Dr Loretta Nastoupil sitere na MD Anderson Cancer Center, Texas n'oge nzukọ ASH 2019. Ọmụmụ ihe nke abụọ lere anya n'ịgwọ ndị ọrịa Follicular lymphoma a na-agwọbeghị mbụ na Obintuzumab (ụdị II anti-CD20 monoclonal antibody) na Lenalidamide (onye na-ahụ maka immunomodulatory), nwere ibu ibu dị elu. A hụrụ nchikota usoro ọgwụgwọ a ka ọ dị mma ma dị irè na nyocha gara aga maka ndị ọrịa na-agwọ na FL na-alaghachi azụ ma ọ bụ na-emegharị emegharị na MD Anderson Cancer Center site n'aka Prof Nathan Fowler (ihe ọmụmụ RELEVANCE).
Dr Allison Barraclough -Nivolumab + Rituximab na eriri afọ nke mbụ.
Dr Barraclough tụlere nsonaazụ nwa oge nke mbụ na ọmụmụ ihe nke abụọ nke ụwa, nke Dr Eliza Hawkes na-eduzi, njikwa ihu n'ihu nke ndị ọrịa nwere ogbo 1-3A follicular lymphoma. Ọmụmụ ihe a na-eji naanị usoro ọgwụgwọ mgbochi ọrịa ngwakọta, nke a nwalere na mbụ na ntọala nlọghachite. Ndị ọrịa na-enweta nivolumab naanị maka izu 8 mbụ ma ọ bụrụ na ha enweta azịza zuru oke, ga-aga n'ihu na otu onye nnọchite nivolumab. Maka ndị nwetara naanị nzaghachi ele mmadụ anya n'ihu ga-aga n'ihu inwe ngwakọta na nivolumab na rituximab. Nsonaazụ dị mma na ọnụego nzaghachi n'ozuzu (ORR) nke 80% na ihe karịrị ọkara nke ndị ọrịa a nwetara nzaghachi zuru oke (CR). Enwere profaịlụ nsi dị ala, ebe ọtụtụ ndị ọrịa ka nwere ike ịrụ ọrụ ma nọgide na-eme ihe omume ndụ nkịtị
Lymphoma nke Mantle
Dr Sasanka Handunetti - Mantle Cell Lymphoma (mmelite nke ọmụmụ AIM).
Dr Handunetti tụlere ihe ngosi ya banyere mmelite afọ atọ nke usoro nke II AIM (TAM, et al, NEJM 2018) emere na Peter MacCallum Cancer Center na Melbourne, na-eji nchikota BTK inhibitor ibrutinib na BCL-2 inhibitor venetoclax ọgwụgwọ na ndị ọrịa nwere. Ọrịa na-adịghị mma prognosis mantle cell lymphoma (MCL). Nsonaazụ gosiri ogologo ndụ n'efu n'etiti etiti ọnwa 29. Ọ welitere ajụjụ ahụ na enwere ike ịnwe obere oge ọgwụgwọ ezubere iche maka onye nnọchi anya na njikwa nke nlọghachite ma ọ bụ refractory MCL.
Prọfesọ Steven Le Gouill - Mantle Cell Lymphoma ọmụmụ.
Prọfesọ Le Gouill tụlere usoro ọmụmụ ya nke m maka MCL achọpụtara ọhụrụ site na iji Ibrutinib, Venetoclax na Obintuzumab bụ ndị egosipụtara na mbụ na ha nwere arụmọrụ na ntọala nlọghachi azụ / mgbagha dị ka ndị nnọchi anya otu yana yana njikọta na nlọghachi azụ / refractory (R / R) MCL. . O nyekwara nkọwa nke ọkọlọtọ nlekọta maka ndị ọrịa nwere MCL maka ndị na-eto eto na ndị agadi na-arịa ọrịa ma n'ihu na njikwa R / R.
Prọfesọ Simon Rule – Mantle Cell Lymphoma Mmelite.
Prọfesọ Simon Rule tụlere ihe ngosi akwụkwọ akụkọ ya na nzukọ ahụ na-elele afọ 7.5 na-esochi ndị ọrịa nwere nlọghachi azụ ma ọ bụ MCL ndị na-arịa ọrịa ibrutinib (BTK inhibitor) nke gosipụtara ọnụ ọgụgụ dị ukwuu nke ndị ọrịa ka nọ na mgbagha karịa afọ 5. O gosikwara na ndị ọrịa natara Ibrutinib n'usoro ọgwụgwọ mbụ nwere nzaghachi na-adịgide adịgide karịa ndị natara ya lateistique.
KTE-X19: Nhọrọ T-cell ụgbọ ala maka Mantle Cell Lymphoma?
Pasent 19 nke ndị ọrịa nwere nlọghachi azụ / refractory mantle cell lymphoma (MCL) zara ọgwụgwọ na KTE-X19, ọgwụgwọ autologous anti-CD2 chimeric antigen receptor (CAR) T-cell therapy, dị ka nsonaazụ sitere na nnwale ZUMA-2019 ewepụtara. na Nzukọ Kwa Afọ XNUMX ASH.
Lymphoma nke Hodgkin
Dr Jessica Hochberg - Chemotherapy, Ndị okenye na-eto eto na Hodgkin Lymphoma.
Ọnụego ọgwụgwọ maka Hodgkin Lymphoma a chọpụtara ọhụrụ dị elu site na iji chemoradiotherapy jikọtara ọnụ. Otú ọ dị, nke a na-ebutekarị ọrụ ọjọọ anụ ahụ na nke psychosocial nke nwere ike imetụta àgwà ndụ n'etiti ndị lanarịrịnụ. Mgbakwunye nke Brentuximab vedotin na Rituximab na nchikota chemotherapy dabara adaba (na-enweghị cyclophosphamide, etoposide ma ọ bụ bleomycin) maka Hodgkin Lymphoma achọpụtara ọhụrụ na-egosi na ọ nweghị nchekwa na ụmụaka, ndị nọ n'afọ iri na ụma na ndị okenye. Nsonaazụ anyị gosipụtara nkwa dị ịrịba ama na ọnụego CR nke 100%, 58% nzaghachi ngwa ngwa n'oge yana mbelata dị ukwuu na ojiji chemotherapy na radieshon. EFS/OS ruo taa bụ 100% nwere oge nleba anya nke karịrị afọ 3.5.
Prọfesọ Andrew Evens - HoLISTIC Hodgkin Lymphoma International Ọmụmụ.
Prọfesọ Evens bụ onye na-arụsi ọrụ ike na HOLISTIC (Hodgkin Lymphoma International Study for Individual Care) - otu mba ụwa na-akwado otu ndị ọkachamara dị iche iche si n'akụkụ ụwa dum iji mụọ akụkụ dị mkpa nke Hodgkin lymphoma prognosis, ọrịa ọrịa, ọgwụgwọ, ịlanarị na nsonaazụ ahụike. gafee afọ niile. Ha na-emekọ data onye ọrịa n'otu n'otu site na ihe karịrị 20 nnwale ụlọ ọgwụ nke oge a sitere na North America na Europe nke afọ niile yana ụlọ ọrụ 6 na mpaghara Hodgkin lymphoma registries, yana nnukwu omume oncology obodo. Ebumnuche ha bụ ịkwalite mkpebi maka ụmụaka na ndị okenye Hodgkin lymphoma ndị ọrịa na ndị na-enye ya, nyere ohere ọgwụgwọ ịgbasawanye yana na enweghị data prognostic zuru oke na ogologo oge.
Dr Stephen Ansell na Deborah Sims - Hodgkin Lymphoma.
Dr Ansell bụ ọkachamara na-eduga na lymphoma na-abụghị Hodgkin na Hodgkin lymphoma na Mayo Clinic, USA. Dr Ansell kwuru banyere Hodgkin lymphoma - n'ihu usoro ọgwụgwọ oge na ASH nke ọ ka gara. Nnọkọ ahụ gosipụtara nnwale ụlọọgwụ nke enwere ike iji ya mee ihe na usoro ọgwụgwọ ọhụụ na ntọala ihu ihu, nke na-agbakwunye Brentuximab Vedotin & onye na-egbochi PD-1 wee belata ụfọdụ kemoterapi ọkọlọtọ nke bụ bleomycin, gosipụtara nsonaazụ pụtara ìhè. Nsonaazụ a belatara nsí maka ndị ọrịa na-anata ọgwụgwọ a ma e jiri ya tụnyere ọgwụgwọ ọkọlọtọ. Ọkọlọtọ ọgwụgwọ na Hodgkin lymphoma nwere elu karịa ọnụego nzaghachi niile ebe ihe dị ka 90% ndị ọrịa na-enweta nzaghachi metabolic zuru oke. Ọtụtụ ule na Hodgkin lymphoma bụ ugbu a iji belata profaịlụ nsi na mmetụta mbubreyo maka ndị ọrịa a.
Akụkụ akụkụ nke Lymphoma
Dr Sasanka Handunetti – Ọmụmụ ihe ọmụmụ nke abụọ na azụghachi azụ ma ọ bụ ngbanwe nke mpaghara Lymphoma.
Dr Handunetti tụlere ihe ngosi akwụkwọ mmado sitere na otu ahụ na Peter MacCallum Cancer Center n'oge nzukọ eji ibrutinib jikọtara ya na venetoclax maka ndị ọrịa nwere nlọghachi azụ ma ọ bụ refractory Marginal Zone Lymphoma (MZL). MZL bụ nsogbu a na-apụghị ịgwọta agwọta nke na-enweghị ọkọlọtọ nlekọta nlekọta na ebe nlọghachi azụ ma ọ bụ nkwụsịtụ. Ahụrụ ọgwụ abụọ a ka ha nwee ihe akaebe nke ọrụ na nnabata dị ka monotherapies (ndị ọrụ otu) na ọmụmụ ihe a bụ iji nyochaa nzaghachi dị ka ọgwụgwọ ngwakọta.
Central Nevous System Lymphoma
Dr Katherine Lewis – Primary Central Nervous System Lymphoma (PCNSL).
Dr Lewis tụlere ihe ngosi akwụkwọ mmado na ASH 2019 nke lere anya nsonaazụ maka ndị ọrịa nwere sistemu akwara etiti ma ọ bụ nke abụọ (ụbụrụ na ọkpụkpụ azụ) lymphoma ejiri Ibrutinib (BTK inhibitor) mesoo. Nke a bụ lymphoma na-adịghị ahụkebe na nke na-eme ihe ike ebe ndị otu onye ọrịa a nwere amụma na-adịghị mma nke a na-ejikarị usoro ọgwụgwọ chemotherapy jikọtara ọnụ. Nke a bụ ihe ọmụmụ nlegharị anya nke nakọtara ozi sitere n'ofe Australia na New Zealand nke ndị ọrịa 16 bụ ndị a na-agwọ monotherapy Ibrutinib na nkwụghachi azụ / nkwụsịtụ. Ọ bụ ezie na ọnụ ọgụgụ dị nta nke ndị ọrịa, nsonaazụ ya na-ekwe nkwa, yana ọnụego nzaghachi ruru 81%.
Macroglobulinemia nke Waldenstrom
Prọfesọ Mathias Rummel – Waldenstrom's Macroglobulinemia & nnwale StiL.
Na-ekpuchi nsonaazụ afọ 2 biputere ọmụmụ StiL na-elele mmezi Rituximab vs observation post bendamustine-rituximab. Nsonaazụ na-egosi na mmezi rituximab anaghị eme ka ndụ zuru oke. Ọkammụta Rummel na-enyekwa nkọwapụta nke njikwa WM ugbu a.
T-cell lymphoma
Mfesa T-cell Lymphoma
Dr Jasmine Zain, MD - na-atụle ọmụmụ ihe kachasị mma na PTCL ewepụtara na ASH 2019.
(Daalụ OBRoncology).
Dr. Zain, Director nke T-cell Lymphoma Programme, Ngalaba Hematology na Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, na-atụle ọmụmụ ihe kachasị mma na ọgwụgwọ nke lymphoma T-cell (PTCL) dị na ASH. 2019.
Dr Jasmine Zain - Kedu ka ọgwụgwọ maka lymphoma T-cell dị n'akụkụ si malite.
(Daalụ OBRoncology).
Dr. Zain, Director nke T-cell Lymphoma Programme, Ngalaba Hematology na Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, na-atụle otú ọgwụgwọ T-cell lymphoma (PCL) dị n'akụkụ si malite n'afọ ndị na-adịbeghị anya.
Dr Jasmine Zain – Akwụkwọ ọhụrụ na-abịaru nso iji gwọọ PTCL gụnyere ọgwụgwọ T-cell CAR.
(Daalụ OBRoncology).
Dr. Zain, Director nke T-cell Lymphoma Programme, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, na-agwa anyị banyere ụfọdụ n'ime akwụkwọ akụkọ na-abịaru nso na mmepe maka ọgwụgwọ nke mpụta T-cell lymphoma. PTCL).
Dr Timothy Illidge, na-akọwa ebumnuche edoro PTCL anya.
(Daalụ OBRoncology).
Dr. Illidge, Prọfesọ nke ezubere iche Therapy na Oncology, Division of Cancer Sciences, Christie Hospital, Mahadum Manchester, na-akọwa nzube nke ezubere iche peripheral t-cell lymphoma (PTCL).
